David Harmon, MD
Massachusetts General Hospital Cancer Center
Center for Sarcoma and Connective
55 Fruit Street, Yawkey 7
Boston, MA 02114
John Mullen, MD Surgeon
"Although we still lack medicines that can be counted on to shrink or slow the growth of chordomas, we are following a variety of exciting leads. Our goal is to keep studying the biology of chordomas to identify targets for chemotherapy and then to make clinical trials available to those who need more than surgery and radiation. "
David Harmon, MD
Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004 Dec;(429):286-91.
DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27.
Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H, Suit HD, Harmon DC. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1213-8.
As a medical oncologist, Dr. Harmon has focused on the care of patients with bone and soft tissue tumors. Because the specialized surgical and radiotherapy expertise of MGH draws patients from all over the world, his clinical practice has included many otherwise rare patients with unresectable or metastatic chordoma.
He has long seen the need for effective new therapies and has participated in clinical trials to develop chemotherapies. Now a critical mass of researchers has directed their attention towards understanding the basic biology of chordoma and to finding new targets for therapy.
Collaborative efforts with other centers are developing a series of clinical trials. Together with Dr. Choy and the rest of the clinical research team he will push these efforts to find cures.
Copyright © 2009 The Massachusetts General Hospital